Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492774 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL25831748 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL5698951 | 1.00 | HTR1A (0.62) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186548 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL15154705 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL2599515 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186572 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL20262054 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186565 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C | |
| SCHEMBL12186569 | 0.82 | HTR1A (0.59) | HTR1AHTR2BCHRM2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | claimed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | claimed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | claimed |
| US-9353096-B2 | Substituted phenylcarbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| EP-2906544-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014056958-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-0516350-B1 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| CN-1069022-A | 4-[2-(2-hydroxyl-2-benzene ethylamino) oxyethyl group that is used for the treatment of obesity and correlation behavior] phenylacetic acid derivatives | ICI PLC (GB) | 1993-02-17 | — | — | CN | disclosed |
| EP-0516350-A2 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| US-4588749-A | ANTIOBESITY AND HYPOGLYCEMIC AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-05-13 | — | — | US | disclosed |
| EP-0040915-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1984-03-21 | — | — | EP | disclosed |
| EP-0040000-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| US-4385066-A | DIETETICS, HYPERGLYCEMIC AGENTS ANTIINFLAMMATORY AGENTS | BEECHAM GROUP LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0040915-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-12-02 | — | — | EP | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | HTR1A 331/4885HTR2B 240/4885CHRM2 326/4885 |
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | HTR1A 135/4885HTR2B 951/4885CHRM2 207/4885 |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | HTR1A 448/4885HTR2B 569/4885CHRM2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.